Udvalget for Humanmedicinske Lægemidler (CHMP) konkluderede, at fordelene ved Rapilysin er større end risiciene for patienter, der har behov for trombolytisk behandling som følge af formodet myokardieinfarkt.
The Committee for Medicinal Products for Human Use (CHMP) decided that Rapilysin’ s benefits are greater than its risks for patients requiring thrombolytic therapy of acute myocardial infarction.